Rexahn Pharmaceuticals (NASDAQ:REXN) Stock Rating Upgraded by Zacks Investment Research

Rexahn Pharmaceuticals (NASDAQ:REXN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Saturday, Zacks.com reports.

According to Zacks, “REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy. “

Other research analysts have also issued reports about the company. ValuEngine upgraded Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 7th. HC Wainwright lowered Rexahn Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 7th. Finally, Ifs Securities lowered Rexahn Pharmaceuticals from a “strong-buy” rating to a “market perform” rating in a report on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $12.63.

REXN stock opened at $1.92 on Friday. The company’s fifty day simple moving average is $2.08. Rexahn Pharmaceuticals has a fifty-two week low of $1.80 and a fifty-two week high of $19.80. The firm has a market cap of $7.72 million, a PE ratio of -0.36 and a beta of 1.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.87 and a quick ratio of 4.87.

Rexahn Pharmaceuticals (NASDAQ:REXN) last released its earnings results on Wednesday, August 7th. The company reported ($0.61) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.95) by $0.34. As a group, equities research analysts forecast that Rexahn Pharmaceuticals will post -2.26 earnings per share for the current year.

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer.

Featured Article: What is the cash asset ratio?

Get a free copy of the Zacks research report on Rexahn Pharmaceuticals (REXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.